These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 173867)

  • 21. Inhibition of Epstein-Barr virus production in P3HR-1 cells by Epstein-Barr virus-seropositive human serum.
    Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Humphreys RE
    Intervirology; 1991; 32(1):37-51. PubMed ID: 1849877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between Epstein-Barr virus nuclear antigen and DNA genome number in superinfected and induced lymphoblastoid cell lines.
    Boguszaková L; Hirsch I; Brichácek B; Vonka V
    J Gen Virol; 1983 Apr; 64 (Pt 4)():887-94. PubMed ID: 6300308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.
    Qualtiere LF; Chase R; Vroman B; Pearson GR
    Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Migration inhibition caused by EBV-specific 48K subcomponent of EBNA and the associated 53K cellular protein.
    Szigeti R; Luka J; Sternås L; Klein G
    Int J Cancer; 1982 Apr; 29(4):413-6. PubMed ID: 6282766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and A2L/AH) with Epstein-Barr virus and the relationship to the C3d receptor.
    Takimoto T; Sato H; Ogura H; Miyawaki T; Glaser R
    Cancer Res; 1986 May; 46(5):2541-4. PubMed ID: 3008992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased macrophage migration inhibition factor production in hamsters sensitized by amoebic antigen and glucan.
    Haq A; Sharma A; Ahmad S
    Parasite Immunol; 1984 Jul; 6(4):391-6. PubMed ID: 6089076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polyploidization of Epstein-Barr virus (EBV)-carrying lymphoma lines decreases the inducibility of EBV-determined early antigen following P3HR-1 virus superinfection or iododeoxyuridine treatment.
    Shapiro IM; Andersson-Anvret M; Klein G
    Intervirology; 1978; 10(2):94-101. PubMed ID: 209000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens.
    Pearson GR; Orr TW
    J Natl Cancer Inst; 1976 Mar; 56(3):485-8. PubMed ID: 176393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigenic content of an in vitro cellular immunity reactive cell surface extract of Raji cells.
    Ng MH; Ng WS; Ho HC
    Arch Virol; 1978; 58(3):213-20. PubMed ID: 215106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
    Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D
    Intervirology; 1975; 5(6):319-34. PubMed ID: 181343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of Epstein-Barr virus transformation: evidence for a block between EBNA production and cell proliferation.
    Pope JH; Moss DJ
    IARC Sci Publ (1971); 1978; (24 Pt 2):617-22. PubMed ID: 221385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional complementation between Epstein-Barr virus and herpesvirus papio.
    Prachová K; Roubal J; Agrba VZ; Timanovskaya VV; Voevodin AF
    Intervirology; 1983; 19(1):52-5. PubMed ID: 6298145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus: comparison of different strains for their biological activities in vitro.
    Furukawa T
    Res Commun Chem Pathol Pharmacol; 1975 Mar; 10(3):543-53. PubMed ID: 166422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of Epstein-Barr virus gene expression by other herpesviruses.
    Kikuta H; Rapp F
    Intervirology; 1988; 29(5):281-91. PubMed ID: 2848780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate.
    Blazar B; Patarroyo M; Klein E; Klein G
    J Exp Med; 1980 Mar; 151(3):614-27. PubMed ID: 6244358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro transfer of cellular immunity against nasopharyngeal carcinoma using transfer factor from donors with Epstein-Barr virus antibody activity.
    Brandes LJ; Goldenberg GJ
    Cancer Res; 1974 Nov; 34(11):3095-101. PubMed ID: 4371172
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of Epstein-Barr virus nuclear antigen(s) in different cell lines by radioimmunoelectrophoresis.
    Sculley TB; Spelsberg TC; Pearson GR
    Intervirology; 1984; 22(4):191-200. PubMed ID: 6096291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal transformation of human leukocytes by Epstein-Barr virus in soft agar.
    Yamamoto N; Hinuma Y
    Int J Cancer; 1976 Feb; 17(2):191-6. PubMed ID: 175028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demonstration of a surface antigen on Epstein-Barr virus genome-carrying lymphoid cells: distinction from the virus-determined membrane antigen.
    Sakamoto K; Hinuma Y
    J Immunol; 1978 May; 120(5):1702-8. PubMed ID: 207776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epstein-Barr virus-specific immunity in asymptomatic carriers of human T-cell leukemia virus type 1].
    Kwon KW
    Hokkaido Igaku Zasshi; 1995 Mar; 70(2):315-28. PubMed ID: 7774883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.